Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Recruitment
Biotech
Pfizer axes phase 3 sickle cell study, cites recruitment issues
Pfizer has terminated one of two phase 3 trials assessing a monoclonal antibody designed to treat sickle cell disease.
Gabrielle Masson
Mar 26, 2024 5:31pm
Layoffs rise 57% YOY in a good, bad and ugly 2023 for biotech
Jan 2, 2024 7:00am
IllumiCare app to help CROs tap patients during consultations
May 10, 2022 8:00am
